Citations

Showing 10 of 108152 citations.

Safety and compatibility of smart device heart rhythm monitoring in patients with cardiovascular implantable electronic devices
Abudan, Anas, Isath, Ameesh , Ryan, J. , Henrich, Mark, Dugan, Jennifer , Ladewig, Dorothy J., Friedman, Paul A. , Abudan, Anas A , Ryan, James D , Henrich, Mark J, Dugan, Jennifer L, Dillon, John J, Friedman, Paul A , Attia, Zachi I. , Dillon, John

Mayo Clinic

Journal of Cardiovascular Electrophysiology | June 13, 2019 | Volume: 30 | Issue: 9 | Pages: 1602-1609

10.1111/jce.14024 | PMID 31190453 Get It

AbstractIntroductionEmerging medical technology has allowed for monitoring of heart rhythm abnormalities using smartphone compatible devices. The safety and utility of such devices have not been established in patients with cardiac implantable electronic devices (CIEDs). We sought to assess the safety and compatibility of the Food and Drug Administration‐approved AliveCor Kardia device in patients with CIEDs.Methods and ResultsWe prospectively recruited patients with CIED for a Kardia recording during their routine device interrogation. A recording was obtained in paced and nonpaced states. Adverse clinical events were noted at the time of recording. Electrograms (EGMs) from the cardiac device were obtained at the time of recording to assess for any electromagnetic interference (EMI) introduced by Kardia. Recordings were analyzed for quality and given a score of 3 (interpretable rhythm, no noise), 2 (interpretable rhythm, significant noise) or 1 (uninterpretable). A total of 251 patients were recruited (59% with a pacemaker and 41% with ICD). There were no adverse clinical events noted at the time of recording and no changes to CIED settings. Review of all EGMs revealed no EMI introduced by Kardia. Recordings were correctly interpreted in 90% of paced recordings (183 had a score of 3, 43 of 2, and 25 of 1) and 94.7% of nonpaced recordings (147 of 3, 15 of 2, and 9 of 1).ConclusionThe AliveCor Kardia device has an excellent safety profile when used in conjunction with most CIEDs. The quality of recordings was preserved in this population. The device, therefore, can be considered for heart rhythm monitoring in patients with CIEDs.
Updates in the management of chronic lymphocytic leukemia/small lymphocytic leukemia
Hanna, Kirollos S.

Mayo Clinic

Journal of Oncology Pharmacy Practice | June 13, 2019 | Volume: 26 | Issue: 1 | Pages: 146-155

10.1177/1078155219853030 | PMID 31189420 Get It

Chronic lymphocytic leukemia is one of the most common lymphoid malignancies. Often treatment modalities are tailored to individual patients based on age, presence of comorbidities and cytogenetics. The advent of ibrutinib has significantly changed the management of the disease in all patient groups and has had the largest impact on clinical practice to date. Over the last 15 years, a series of trials have established that chemoimmunotherapy improves both progression-free survival and overall survival compared to chemotherapy alone. Despite its proven role, efficacy of ibrutinib has not been well established in young, fit patients and in comparison with standard care and as combination therapy with other agents such as venetoclax. New data have strengthened the role of ibrutinib in the front-line setting and establish its place in therapy. In addition, combination therapies are geared to achieve negative minimal residual disease and allow patients to potentially be off of therapy. The management of this leukemia has extensively changed over the past years, and this review article will aim to highlight key trials that have changed practice and led to guideline updates. It is not unlikely that treatment modalities will continue to improve in light of new data.
Deactivating a Pacemaker in Home Care Hospice: Experiences of the Family Caregivers of a Terminally Ill Patient
Kutcher, Gregory R., Soroka, Jacek T.

Mayo Clinic

American Journal of Hospice and Palliative Medicine® | June 13, 2019 | Volume: 37 | Issue: 1 | Pages: 52-57

10.1177/1049909119855608 | PMID 31189325 Get It

Objectives: Although the experiences of family members who care for relatives at the end of life have been researched extensively, little is known about the needs and experiences of families caring for hospice patients with pacemakers. Aim: To better understand the experiences of family caregivers of a terminally ill patient who received hospice care at home and chose deactivation of a pacemaker. Design: The exploratory, cross-sectional design involved semistructured, in-depth interviews. A narrative analysis focusing on form and content was chosen to analyze the data. Participants: Five bereaved caregivers from the Midwestern United States who provided care and participated in the deactivation of their family member’s pacemaker. Results: Four storylines that described, gave meaning to, and contextualized the caregivers’ experiences were identified: “I am done. I am not doing it anymore”; “Whatever you decide, I’ll support you”; “It is really difficult to watch, but you want to be there”; and “I will not have part of this.” Caregivers struggled with lack of support, understanding, and acceptance from medical providers when their family member decided to have her pacemaker deactivated, and they believed that the hospice model of care was appropriate to support and help them in that process. Conclusions: This research aids in understanding the ramifications of family-provided end-of-life care to a patient whose pacemaker has been deactivated. This can help to increase hospice clinicians’ knowledge regarding caregivers’ experiences facing deactivation of a pacemaker, before and after the patient’s death.
Relationship of Activity Patterns to Acute Mountain Sickness in South Pole Workers
Pathangey, Girish , Wheatley, Courtney M. , Stewart, Glenn M. , Anderson, Paul J., Richert, Maile L. Ceridon, Johnson, Jacob, Johnson, Bruce D., Wheatley-Guy, Courtney M, Johnson, Jacob B, Miller, Andrew D., Pathangey, Girish

Mayo Clinic

International Journal of Sports Medicine | June 12, 2019 | Volume: 40 | Issue: 07 | Pages: 440-446

10.1055/a-0884-3014 | PMID 31189189 Get It

AbstractThis study aimed to evaluate the influence of physical activity on incidence of acute mountain sickness (AMS) by continuous activity monitoring in a free-living sample of South Pole workers over the initial 72 h at altitude exposure of 2,840 m (9,318 ft). Body Media activity monitors were worn by 47 healthy participants. AMS was defined by the Lake Louise symptom questionnaire. Venous blood samples were taken at sea level and approximately 48 h after high altitude exposure. AMS incidence was 34% (n=16/47) over the first 48 h and 40% (n=19/47) over 72 h. On day 2 at high altitude, individuals with AMS demonstrated a significantly greater increase in the percent change in physical activity metrics from baseline: total energy expenditure 19±13 vs. 5±7%, total steps 65±51 vs. 10±18%, metabolic equivalent of tasks 21±13 vs. 7±13%, and time spent performing moderate to vigorous physical activity 114±79 vs. 26±27% for individuals with AMS vs. no AMS, respectively, p<0.05. In addition, erythropoietin and vascular endothelial growth factor were 1.69 and 1.75 times higher, respectively, in those with AMS. In conclusion, workers who engaged in increased physical activity and activity intensity during initial exposure to the South Pole were more susceptible to developing AMS.
TRAILshort Protects against CD4 T Cell Death during Acute HIV Infection
Natesampillai, Sekar, Paim, Ana C. , Cummins, Nathan W. , Chandrasekar, Aswath P. , Bren, Gary D., Lewin, Sharon R. , Badley, Andrew D. , Cummins, Nathan W , Badley, Andrew D , Kiem, Hans‐Peter

Mayo Clinic

The Journal of Immunology | June 12, 2019 | Volume: 203 | Issue: 3 | Pages: 718-724

10.4049/jimmunol.1900271 | PMID 31189571 Get It

Abstract CD4 T cells from HIV-1 infected patients die at excessive rates compared to those from uninfected patients, causing immunodeficiency. We previously identified a dominant negative ligand that antagonizes the TRAIL-dependent pathway of cell death, which we called TRAILshort. Because the TRAIL pathway has been implicated in CD4 T cell death occurring during HIV-1 infection, we used short hairpin RNA knockdown, CRISPR deletion, or Abs specific for TRAILshort to determine the effect of inhibiting TRAILshort on the outcome of experimental acute HIV infection in vitro. Strikingly, all three approaches to TRAILshort deletion/inhibition enhanced HIV-induced death of both infected and uninfected human CD4 T cells. Thus, TRAILshort impacts T cell dynamics during HIV infection, and inhibiting TRAILshort causes more HIV-infected and uninfected bystander cells to die. TRAILshort is, therefore, a host-derived, host-adaptive mechanism to limit the effects of TRAIL-induced cell death. Further studies on the effects of TRAILshort in other disease states are warranted.
Biologic Significance of Magnetic Resonance Imaging Invisibility in Localized Prostate Cancer
Salami, Simpa S. , Kaplan, Jeremy , Nallandhighal, Srinivas , Takhar, Mandeep, Tosoian, Jeffrey J. , Lee, Matthew , Yoon, Junhee, Plouffe, Komal , Kaffenberger, Samuel D. , Schaeffer, Edward M. , Karnes, R. Jeffrey , George, Arvin K. , Montgomery, Jeffrey S., You, Sungyong , Tomlins, Scott A. , Curci, Nicole E. , Kim, Hyung L. , Spratt, Daniel E. , Palapattu, Ganesh S. , Spratt, Daniel E , Kim, Hyung L , Salami, Simpa S , Hovelson, Daniel H. , Lotan, Tamara Levin , Morgan, Todd M. , Davenport, Matthew S. , Udager, Aaron M , Lee, Matthew S

Mayo Clinic

JCO Precision Oncology | June 12, 2019 | Volume: No volume available | Issue: 3 | Pages: 1-12

10.1200/po.19.00054 | PMID 32914029 Get It

PURPOSE Multiparametric magnetic resonance imaging (mpMRI) is used widely for prostate cancer (PCa) evaluation. Approximately 35% of aggressive tumors, however, are not visible on mpMRI. We sought to identify the molecular alterations associated with mpMRI-invisible tumors and determine whether mpMRI visibility is associated with PCa prognosis. METHODS Discovery and validation cohorts included patients who underwent mpMRI before radical prostatectomy and were found to harbor both mpMRI-visible (Prostate Imaging and Reporting Data System 3 to 5) and -invisible (Prostate Imaging and Reporting Data System 1 or 2) foci on surgical pathology. Next-generation sequencing was performed to determine differential gene expression between mpMRI-visible and -invisible foci. A genetic signature for tumor mpMRI visibility was derived in the discovery cohort and assessed in an independent validation cohort. Its association with long-term oncologic outcomes was evaluated in a separate testing cohort. RESULTS The discovery cohort included 10 patients with 26 distinct PCa foci on surgical pathology, of which 12 (46%) were visible and 14 (54%) were invisible on preoperative mpMRI. Next-generation sequencing detected prioritized genetic mutations in 14 (54%) tumor foci (n = 8 mpMRI visible, n = 6 mpMRI invisible). A nine-gene signature (composed largely of cell organization/structure genes) associated with mpMRI visibility was derived (area under the curve = 0.89), and the signature predicted MRI visibility with 75% sensitivity and 100% specificity (area under the curve = 0.88) in the validation cohort. In the testing cohort (n = 375, median follow-up 8 years) there was no significant difference in biochemical recurrence, distant metastasis, or cancer-specific mortality in patients with predicted mpMRI-visible versus -invisible tumors (all P > .05). CONCLUSION Compared with mpMRI-invisible disease, mpMRI-visible tumors are associated with underexpression of cellular organization genes. mpMRI visibility does not seem to be predictive of long-term cancer outcomes, highlighting the need for biopsy strategies that detect mpMRI-invisible tumors.
Outcomes Following Treatment of the Infected Achilles Tendon
Bowers, Mark , Turner, Norman S. , Ryssman, Daniel B., Moran, Steven L. , Bowers, Mark W

Mayo Clinic

Foot & Ankle Orthopaedics | June 12, 2019 | Volume: 4 | Issue: 2 | Pages: No page available

10.1177/2473011419846943 | PMID 35097326 Get It

Background: Infection following Achilles tendon surgery is a devastating complication and can be difficult to treat and often leads to poor outcomes. A number of treatments have been described, but there is little information concerning outcomes of these treatments. Our purpose was to evaluate the clinical and functional outcomes of patients who have undergone treatment for an infected Achilles tendon after acute and chronic midsubstance repair. Methods: We retrospectively reviewed the medical records of 20 patients who had undergone surgical treatment for an infected Achilles tendon between 2000 and 2016. The mean follow-up time was 21 months (range, 2-68 months). All patients underwent extensive debridement of the tendon with removal of all infected tissue and foreign material. Soft tissue wound coverage was utilized for large wounds that were not amenable to primary or secondary closure. All patients received culture-specific intravenous (IV) antibiotics for 3 to 6 weeks. Postoperatively, the extremity was immobilized in a splint followed by a cast until the wound was healed. The cast was then replaced with a walking boot and the patients were provided a physical therapy program. Functional outcomes were measured using the Foot and Ankle Ability Measure (FAAM) Activity of Daily Living (ADL) scale. Results: All wounds had healed at the time of last follow-up. Three patients (15%) required an unplanned return to the operating room for repeat debridement. All patients were able to walk without the use of a gait aid. Five patients (25%) required continued use of a boot or brace during ambulation. Fourteen patients participated in the FAAM ADL survey. There were 6 patients lost to follow-up. The average FAAM score was 87 (range, 71.4-100). At last follow-up, most patients reported their overall function as “normal” or “nearly normal.” Eradication of infection and satisfactory functional results can be attained after radical debridement, wound closure, and administration of culture-specific IV antibiotics. Level of Evidence: Level IV, retrospective case series.
Regulation of renal NaDC1 expression and citrate excretion by NBCe1-A
Osis, Gunars , Webster, Kierstin L. , Harris, Autumn N. , Lee, Hyun‐Wook , Chen, Chao , Fang, Lijuan, Romero, Michael F. , Khattri, Ram B. , Merritt, Matthew E. , Verlander, Jill W. , Weiner, I. David , Weiner, I David , Romero, Michael F

Mayo Clinic

American Journal of Physiology-Renal Physiology | June 12, 2019 | Volume: 317 | Issue: 2 | Pages: F489-F501

10.1152/ajprenal.00015.2019 | PMID 31188034 Get It

Citrate is critical for acid-base homeostasis and to prevent calcium nephrolithiasis. Both metabolic acidosis and hypokalemia decrease citrate excretion and increase expression of Na+-dicarboxylate cotransporter 1 (NaDC1; SLC13A2), the primary protein involved in citrate reabsorption. However, the mechanisms transducing extracellular signals and mediating these responses are incompletely understood. The purpose of the present study was to determine the role of the Na+-coupled electrogenic bicarbonate cotransporter (NBCe1) A variant (NBCe1-A) in citrate metabolism under basal conditions and in response to acid loading and hypokalemia. NBCe1-A deletion increased citrate excretion and decreased NaDC1 expression in the proximal convoluted tubules (PCT) and proximal straight tubules (PST) in the medullary ray (PST-MR) but not in the PST in the outer medulla (PST-OM). Acid loading wild-type (WT) mice decreased citrate excretion. NaDC1 expression increased only in the PCT and PST-MR and not in the PST-MR. In NBCe1-A knockout (KO) mice, the acid loading change in citrate excretion was unaffected, changes in PCT NaDC1 expression were blocked, and there was an adaptive increase in PST-MR. Hypokalemia in WT mice decreased citrate excretion; NaDC1 expression increased only in the PCT and PST-MR. NBCe1-A KO blocked both the citrate and NaDC1 changes. We conclude that 1) adaptive changes in NaDC1 expression in response to metabolic acidosis and hypokalemia occur specifically in the PCT and PST-MR, i.e., in cortical proximal tubule segments; 2) NBCe1-A is necessary for normal basal, metabolic acidosis and hypokalemia-stimulated citrate metabolism and does so by regulating NaDC1 expression in cortical proximal tubule segments; and 3) adaptive increases in PST-OM NaDC1 expression occur in NBCe1-A KO mice in response to acid loading that do not occur in WT mice.
Does Donor Allograft Microsteatosis Matter? Comparison of Outcomes in Liver Transplantation With a Propensity‐Matched Cohort
Croome, Kristopher P. , Lee, David D. , Croome, Sarah, Nakhleh, Raouf E. , Senada, Peter A., Yataco, Maria, Abader Sedki Senada, Peter, Livingston, David, Taner, C. Burcin , Croome, Kris P , Lee, David D , Livingston, David H.

Mayo Clinic

Liver Transplantation | June 12, 2019 | Volume: 25 | Issue: 10 | Pages: 1533-1540

10.1002/lt.25583 | PMID 31187923 Get It

It has been suggested that microsteatosis does not negatively impact graft survival following liver transplantation (LT). The present study represents the largest series on donor livers with significant microsteatosis and investigates the impact of microsteatosis on perioperative factors such as postreperfusion syndrome (PRS), early allograft dysfunction (EAD), and postoperative renal dysfunction. Clinical outcomes of all patients undergoing LT with donor livers with isolated microsteatosis (≥30%; n = 239) between 2000 and 2017 were compared with a propensity score–matched cohort of patients undergoing LT with donor livers with no steatosis (n = 239). Patients in the microsteatosis group had a higher rate of PRS (33.1% versus 24.2%; P = 0.03), EAD (38.2% versus 23.0%; P < 0.001), and continuous renal replacement therapy (CRRT) requirement following LT (10.9% versus 3.6%; P = 0.002) than the no steatosis group. No difference in patient (P = 0.33) or graft survival (P = 0.18) was observed between the 2 groups. On multivariate regression, livers with microsteatosis had an increased risk of graft loss with retransplant recipients (hazard ratio [HR], 1.59; P < 0.001), increasing Model for End‐Stage Liver Disease (MELD) score (HR, 1.13; P = 0.01), and organs from donation after circulatory death donors (HR, 1.46; P = 0.003). In conclusion, recipients of donor livers with significant microsteatosis are at an increased risk of PRS, EAD, and postoperative renal dysfunction requiring CRRT. Livers with significant microsteatosis should be avoided in retransplant recipients and in recipients with high biological MELD scores. Once appropriately selected recipients of these livers are able to overcome the initial perioperative implications of using these donor livers, longterm patient and graft survival is similar to recipients receiving grafts with no steatosis.
EXPLORATORY BIOMARKER ANALYSIS IN THE PH 3 ECHELON‐1 STUDY: WORSE OUTCOME WITH ABVD IN PATIENTS WITH ELEVATED BASELINE LEVELS OF SCD30 AND TARC
Younes, Anas , Gallamini, Andrea , Ansell, Stephen M. , Kim, W.S., Kalakonda, Nagesh , Kaminski, Mark , Pettengell, Ruth , Onsum, Matthew, Josephson, Neil C. , Liu, R., Miao, Harry , Gautam, Ashish , Trepicchio, William L. , Sureda, Anna , Radford, John , Connors, Joseph M. , Cheong, June‐Won , Flinn, Ian W. , Kuroda, Shingo

Mayo Clinic

Hematological Oncology | June 12, 2019 | Volume: 37 | Issue: S2 | Pages: 290-291

10.1002/hon.99_2630 Get It